Nivobotulinumtoxina clinical trials
Also written MT10109L and MT10109.
How each study uses nivobotulinumtoxina is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2018 | 4 |
| 2019 | 1 |
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses nivobotulinumtoxina is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)CompletedPhase 3Medy-ToxNCT04157686Written as MT10109L Dose 1
- Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar LinesCompletedPhase 2Medy-ToxNCT01485601Written as MT10109
- MT10109L in the Treatment of Lateral Canthal LinesCompletedPhase 3Medy-ToxNCT03785145Written as MT10109L
- MT10109L in the Treatment of Glabellar LinesCompletedPhase 3Medy-ToxNCT03795922Written as MT10109L
- MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar LinesCompletedPhase 3Medy-ToxNCT03732833Written as MT10109L
- MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)CompletedPhase 3Medy-ToxNCT03721016Written as MT10109L
- Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical DystoniaCompletedPhase 2Medy-ToxNCT01588574Written as MT10109
Codes
What other systems call nivobotulinumtoxina · ClinicalTrials.gg INT017803
- UNII (FDA) RKC2ICC0TONIVOBOTULINUMTOXINAOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RKC2ICC0TO | NIVOBOTULINUMTOXINA | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.